Patricia Tennis

Expertise

Therapeutic Outcomes and Safety
Drug Safety
Pharmacoepidemiology

Biography

Patricia Tennis, PhD, is a senior director in epidemiology, RTI Health Solutions. Dr. Tennis came to RTI in 2002 from the pharmaceutical industry, where she helped design and implement drug safety studies and risk management activities related to use of medications. She has focused on epilepsy and drug safety, collaborating on several studies of antiepileptic drugs in pregnancy and on safety studies of other medications in neurology, psychiatry, respiratory, and metabolic diseases. She has overseen numerous epidemiology studies and participated in regulatory discussions of drug safety issues with U.S., Canadian, and European agencies. Dr. Tennis has been the lead epidemiologist on multiple international pregnancy exposure registries, studies that required coordination across multiple countries and sites, and has led projects to evaluate the effectiveness of Risk Minimization Action Plans. She is a leading researcher in pharmacoepidemiology and a fellow of the International Society for Pharmacoepidemiology.

Education

MPH, Epidemiology, University of North Carolina at Chapel Hill; PhD, Biology, Case Western Reserve University; MS, Biology, Case Western Reserve University; BS, Zoology, University of Wisconsin.

Selected Publications

Rubino, A., McQuay, L., Gough, S.C., Kvasz, M., & Tennis, P. (2007 Dec). Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with Type 2 diabetes: A population-based analysis in the UK. Diabetic Medicine, 24 (12):1412-1418.

Andrews, E.B., & Tennis, P. (Nov 2007). Promise and pitfalls of administrative data in evaluating pregnancy outcomes. Pharmacoepidemiology and Drug Safety, 16 (11):1181-1183.

Rubino, A., Roskell, N.S., Tennis, P., Mines, D., Weich, S., & Andrews, E. (2007 Feb 03). Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: Retrospective cohort study. BMJ, 334 (7587):242-245.

Tennis, P., Andrews, E., Hickman, P., Miller, D., Hollis, K.A., & Cook, S. (Feb 2007). The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme. Alimentary Pharmacology and Therapeutics, 25 (3):317-322.

Miller, D.P., Bennett, L., Hollis, K.A., Tennis, P., Cook, S.F., & Andrews, E. (September 2006). A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Alimentary Pharmacology and Therapeutics, 24 (5):869-878.

Tennis, P., Sherrill, B., Fernandez, C., & Dolan, C. (2005). Cancer risk in asthmatic populations. Annals of Allergy Asthma and Immunology, 95 (4):354-60.

Mockenhaupt, M., Messenheimer, J., Tennis, P., & Schlingmann, J. (April 2005). Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology, 64 (7):1134-8.

Morrell, M.J., Isojarvi, J., Taylor, A.E., Dam, M., Ayala, R., Gomez, G., O'Neill, F., Tennis, P., & Messenheimer, J. (May 2003). Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Research , 54 (2-3):189-199.

Tennis, P., & Eldridge, R.R. (2002 Oct). Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia, 43 (10):1161-1167.

Tennis, P., & Stern, R.S. (August 1997). Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: A record linkage study. Neurology, 49 (2):542-6.

View all publications by Patricia Tennis…